High-fat diet (HFD)-induced inflammation is characterized by widespread infiltration of inflammatory cells across multiple organs. Celastrol, an emerging drug derived from Tripterygiumwilfordii, has demonstrated anti-inflammatory effects in multiple models, including ApoE-knockout mice. However, quantitative evaluation of multi-organ histopathological inflammation and its association with systemic inflammatory response remains to be determined. This study aimed to evaluate anti-inflammatory effects of celastrol in multi-organ via Hematoxylin and Eosin (H&E)-stained tissues and its association with systemic inflammation through circulating TNF-α levels in HFD-fed ApoE-knockout mice. Male ApoE-knockout mice were divided into five groups (n=6/group). Four groups were fed an HFD for 12 weeks, while the control group received a normal diet. During the last 4 weeks, three HFD groups received intraperitoneal celastrol (1.5, 2, and 2.5 mg/kg/day), while controls received 2% DMSO/day. At the end of the treatment, the heart, lungs, liver, and kidneys were harvested for H&E staining, and inflammatory cell infiltration was quantified using NDP.view 2. Plasma TNF-α levels were measured using ELISA. The 2.5mg celastrol-treated group showed a significant reduction in the area of inflammatory cell infiltration across all organs compared to the HFD group (heart, p<0.01; lung, p<0.001; liver, p<0.05; kidney, p<0.01). Additionally, 2 and 2.5 mg of celastrol were reported to significantly decrease plasma TNF-α levels (p<0.05). Celastrol attenuates multi-organ histopathological inflammation and reduces circulating TNF-α levels in HFD-fed ApoE-knockout mice, supporting its potential as a multi-target anti-inflammatory agent. Further studies are required to elucidate the underlying mechanisms.